<a href="https://laohu8.com/S/ZVSA">Zyversa Therapeutics</a> Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements
ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550(a)(2). Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol "ZVSA." This move might pose challenges for stockholders due to a potentially limited market for trading shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019856), on July 16, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。